Zepbound — the brand name for tirzepatide — is the most effective GLP-1 medication for weight loss, according to one study.

A pronouncement from President Trump about the category drove their share prices down, although not to bargain-basement ...

Tirzepatide conferred significantly greater weight loss than semaglutide at 72 weeks for adults with overweight or obesity, ...

For the 2025 outlook, Novo Nordisk now expects 13-21% revenue increase at constant exchange rates (CER). Operating profit is expected at 16-24% growth. However, this forecast, 3% lower for revenue and ...

President Donald Trump's executive order directs pharmaceutical companies to lower their prices to levels closer to those ...

Digital programs incorporating behavioral therapy led to solid reductions in body weight, and did so at lower drug doses.

GlobalData analysis predicts the global GLP-1RA market will reach $168bn by 2033, with Novo Nordisk and Eli Lilly to dominate ...

Reducing exposure to medicines is always a good thing if similar clinical outcomes can be achieved, and the study suggests it ...

People taking Eli Lilly's obesity drug, Zepbound, lost nearly 50% more weight than those using rival Novo Nordisk's Wegovy in the first head-to-head study of the blockbuster medications. Clinical ...

In the first direct comparison study involving individuals with obesity, tirzepatide demonstrated approximately 50% greater ...

As medications become increasingly popular to support weight loss, not all of them are approved by the U.S. Food and Drug ...